Talk:Fluticasone furoate/vilanterol
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Fluticasone furoate/vilanterol.
|
Refs not about topic in question
So moved here.
Extended content
|
|---|
|
Fluticasone Furoate, an inhaled corticosteroid, has been shown to have a potent pharmacological profile on a respiratory inflammation disease in animal studies. It was described as being safe and effective.[1] Additionally, inhaled corticosteroids have been shown to have a beneficial risk/benefit ratio in patients over multiple studies, with that caveat that chronic use be monitored.[2] They were also shown to have a favorable risk/benefit ratio in the treatment of patients with Chronic Obstructive Pulmonary Disorder (COPD).[3] Similarly, Vilanterol was shown to be a potent, selective ß2 Adrenoceptor agonist with a long duration of action.[4] Long-acting ß2 Adrenoceptor agonists were shown to be safe for use in patients with stable moderate-to-severe COPD in another systematic review.[5] |
Doc James (talk · contribs · email) 19:11, 20 November 2016 (UTC)
References
- ^ Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol - Lung Cell Mol Physiol. 2007;293(3).
- ^ Passalacqua G, Albano M, Canonica GW, et al. Inhaled and nasal corticosteroids: safety aspects*. Allergy. 2000;55(1):16-33. doi:10.1034/j.1398-9995.2000.00370.x.
- ^ Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med. 2006;4(3):253-262. doi:10.1370/afm.517.
- ^ Slack RJ, Barrett VJ, Morrison VS, et al. In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting β2-Adrenoceptor Agonist with 24-Hour Duration of Action. J Pharmacol Exp Ther. 2012;344(1).
- ^ Jaeschke R, O’Byrne PM, Mejza F, et al. The Safety of Long-Acting β-Agonists among Patients with Asthma Using Inhaled Corticosteroids. Am J Respir Crit Care Med. 2008;178(10):1009-1016. doi:10.1164/rccm.200804-494OC.